{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:15:03Z","timestamp":1784121303455,"version":"3.55.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Kaposi sarcoma (KS)-associated herpesvirus (KSHV)\u2013associated multicentric Castleman disease (MCD) is a relapsing and remitting systemic lymphoproliferative disorder characterized by severe inflammatory symptoms most common among people living with HIV (PLWH). Patients with KSHV-MCD may present with concurrent KSHV-associated diseases, such as KS and\/or primary effusion lymphoma (PEL). We evaluated clinical and immunologic characteristics, the effects of concurrent KSHV malignancies, and treatments from the largest prospective natural history study of participants with KSHV-MCD within the United States. Treatment options administered at investigator discretion included high-dose zidovudine with valganciclovir (AZT\/VGC), rituximab, or rituximab with liposomal doxorubicin (R-Dox) during KSHV-MCD flares. Survival analyses and prognostic factors were explored for all participants. Sixty-two participants with HIV were enrolled, including 20 with KSHV-MCD alone, 34 with KSHV-MCD and KS, 1 with KSHV-MCD and PEL, and 7 with all KSHV-associated diseases. Forty-four percent of KSHV-MCD diagnoses were made at our institution. Forty-four participants received rituximab-based therapies, 20 of whom had maintenance AZT\/VGC or interferon. Participants receiving R-Dox and then maintenance AZT\/VGC had the highest 5-year progression-free survival (89%). Cytokine profiles during KSHV-MCD flares did not differ by the presence of concurrent KSHV-associated diseases. The 10-year survival was 71% (95% confidence interval [CI], 56% to 82%) for all participants. A concurrent diagnosis of PEL negatively impacted survival (PEL hazard ratio, 5.4; 95% CI, 1.8 to 16.8). KSHV-MCD is an underdiagnosed condition among PLWH, including those with KS. KSHV-MCD has an excellent prognosis with appropriate treatment. Physicians should be alert for patients with multiple KSHV diseases, which impact optimal treatment and survival outcomes. This study was registered at www.clinicaltrials.gov as #NCT00099073.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020004058","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T15:35:39Z","timestamp":1615822539000},"page":"1660-1670","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":74,"title":["Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5709-4675","authenticated-orcid":false,"given":"Ramya","family":"Ramaswami","sequence":"first","affiliation":[{"name":"HIV & AIDS Malignancy Branch and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5794-7292","authenticated-orcid":false,"given":"Kathryn","family":"Lurain","sequence":"additional","affiliation":[{"name":"HIV & AIDS Malignancy Branch and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark N.","family":"Polizzotto","sequence":"additional","affiliation":[{"name":"HIV & AIDS Malignancy Branch and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ekwede","sequence":"additional","affiliation":[{"name":"HIV & AIDS Malignancy Branch and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsta","family":"Waldon","sequence":"additional","affiliation":[{"name":"HIV & AIDS Malignancy Branch and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Mangusan","sequence":"additional","affiliation":[{"name":"HIV & AIDS Malignancy Branch and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anaida","family":"Widell","sequence":"additional","affiliation":[{"name":"HIV & AIDS Malignancy Branch and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Rupert","sequence":"additional","affiliation":[{"name":"AIDS Monitoring Laboratory, Leidos Biomedical Research, Frederick, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jomy","family":"George","sequence":"additional","affiliation":[{"name":"Clinical Pharmacokinetics Research Laboratory, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila H.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"HIV & AIDS Malignancy Branch and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie A.","family":"Marshall","sequence":"additional","affiliation":[{"name":"Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical, Frederick National Laboratory for Cancer Research, Frederick, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Whitby","sequence":"additional","affiliation":[{"name":"Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical, Frederick National Laboratory for Cancer Research, Frederick, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7688-1439","authenticated-orcid":false,"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-0301","authenticated-orcid":false,"given":"Elaine S.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Little","sequence":"additional","affiliation":[{"name":"HIV & AIDS Malignancy Branch and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Uldrick","sequence":"additional","affiliation":[{"name":"HIV & AIDS Malignancy Branch and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3057-1395","authenticated-orcid":false,"given":"Robert","family":"Yarchoan","sequence":"additional","affiliation":[{"name":"HIV & AIDS Malignancy Branch and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"issue":"11","key":"2021031515350999300_B1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-associated cancers and related diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2021031515350999300_B2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-019-0060-9","article-title":"Kaposi sarcoma","volume":"5","author":"Cesarman","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"5192","key":"2021031515350999300_B3","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1126\/science.7997879","article-title":"Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi\u2019s sarcoma","volume":"266","author":"Chang","year":"1994","journal-title":"Science"},{"issue":"1","key":"2021031515350999300_B4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00002030-199601000-00009","article-title":"Multicentric Castleman\u2019s disease in HIV infection: a clinical and pathological study of 20 patients","volume":"10","author":"Oksenhendler","year":"1996","journal-title":"AIDS"},{"issue":"8","key":"2021031515350999300_B5","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/02841860410002752","article-title":"Fifty years of multicentric Castleman\u2019s disease","volume":"43","author":"Waterston","year":"2004","journal-title":"Acta Oncol"},{"issue":"8","key":"2021031515350999300_B6","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1182\/blood.V97.8.2526","article-title":"Serum viral interleukin-6 in AIDS-related multicentric Castleman disease","volume":"97","author":"Aoki","year":"2001","journal-title":"Blood"},{"issue":"26","key":"2021031515350999300_B7","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1182\/blood-2013-08-519959","article-title":"Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"122","author":"Polizzotto","year":"2013","journal-title":"Blood"},{"issue":"24","key":"2021031515350999300_B8","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood-2014-07-586800","article-title":"Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease","volume":"124","author":"Uldrick","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2021031515350999300_B9","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2010-07-290213","article-title":"How I treat HIV-associated multicentric Castleman disease","volume":"116","author":"Bower","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2021031515350999300_B10","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood.V96.6.2069.h8002069_2069_2073","article-title":"High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients","volume":"96","author":"Oksenhendler","year":"2000","journal-title":"Blood"},{"issue":"16","key":"2021031515350999300_B11","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2019-01-893339","article-title":"Viral, immunologic, and clinical features of primary effusion lymphoma","volume":"133","author":"Lurain","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2021031515350999300_B12","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood.V99.7.2331","article-title":"High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease","volume":"99","author":"Oksenhendler","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2021031515350999300_B13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0002-9440(10)64940-1","article-title":"Differential viral protein expression in Kaposi\u2019s sarcoma-associated herpesvirus-infected diseases: Kaposi\u2019s sarcoma, primary effusion lymphoma, and multicentric Castleman\u2019s disease","volume":"156","author":"Parravicini","year":"2000","journal-title":"Am J Pathol"},{"issue":"7","key":"2021031515350999300_B14","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1182\/blood.V97.7.2130","article-title":"Kaposi sarcoma-associated herpesvirus infects monotypic (IgM \u03bb) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders","volume":"97","author":"Du","year":"2001","journal-title":"Blood"},{"issue":"5","key":"2021031515350999300_B15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2559.2008.03144.x","article-title":"Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+ multicentric Castleman disease (MCD)","volume":"53","author":"Chadburn","year":"2008","journal-title":"Histopathology"},{"issue":"13","key":"2021031515350999300_B16","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1182\/blood-2011-02-333633","article-title":"Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease","volume":"118","author":"Hoffmann","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2021031515350999300_B17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.hoc.2017.09.007","article-title":"Treatment of kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"32","author":"Lurain","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"50","key":"2021031515350999300_B18","doi-asserted-by":"crossref","first-page":"12805","DOI":"10.1073\/pnas.1816183115","article-title":"Discovery of Kaposi\u2019s sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA","volume":"115","author":"Tagawa","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"2021031515350999300_B19","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2007.10.6732","article-title":"Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman\u2019s disease: ANRS 117 CastlemaB Trial","volume":"25","author":"G\u00e9rard","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021031515350999300_B20","article-title":"Relapse of multicentric Castlemans disease following Rituximab based therapy in HIV-positive patients","author":"Dalla Pria","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2021031515350999300_B21","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1182\/blood.V97.10.3244","article-title":"Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus","volume":"97","author":"Davis","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2021031515350999300_B22","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1128\/JVI.74.2.684-692.2000","article-title":"Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir","volume":"74","author":"Gustafson","year":"2000","journal-title":"J Virol"},{"issue":"6","key":"2021031515350999300_B23","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1128\/JVI.73.6.4786-4793.1999","article-title":"Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir","volume":"73","author":"Cannon","year":"1999","journal-title":"J Virol"},{"issue":"26","key":"2021031515350999300_B24","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1182\/blood-2010-11-317610","article-title":"High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy","volume":"117","author":"Uldrick","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2021031515350999300_B25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/ajcp\/aqw218","article-title":"HHV8\/KSHV-positive lymphoproliferative disorders and the spectrum of plasmablastic and plasma cell neoplasms: 2015 SH\/EAHP Workshop Report\u2013part 3","volume":"147","author":"Chadburn","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"2021031515350999300_B26","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues: World Health Organization Classification of Tumours","author":"Swerdlow","year":"2017"},{"issue":"25","key":"2021031515350999300_B27","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood.2019004602","article-title":"Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"135","author":"Ramaswami","year":"2020","journal-title":"Blood"},{"issue":"27","key":"2021031515350999300_B28","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"2021031515350999300_B29","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"issue":"RR-4","key":"2021031515350999300_B30","first-page":"1","article-title":"Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America","volume":"58","author":"Kaplan","year":"2009","journal-title":"MMWR Recomm Rep"},{"issue":"24","key":"2021031515350999300_B31","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood-2014-07-586800","article-title":"Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease","volume":"124","author":"Uldrick","year":"2014","journal-title":"Blood"},{"key":"2021031515350999300_B32","volume-title":"Proinflammatory Panel 1 (Human)","author":"Meso Scale Diagnostics","year":"2020"},{"issue":"19","key":"2021031515350999300_B33","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1200\/JCO.2005.07.084","article-title":"Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS","volume":"23","author":"Boulanger","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"2021031515350999300_B34","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood.V104.11.2286.2286","article-title":"Prognostic factors and outcome of human herpesvirus 8 (KSHV\/HHV-8)-associated primary effusion lymphoma (PEL) in patients with AIDS","volume":"104","author":"Boulanger","year":"2004","journal-title":"Blood"},{"key":"2021031515350999300_B35","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3389\/fimmu.2017.01758","article-title":"Interplay between janus kinase\/signal transducer and activator of transcription signaling activated by type I interferons and viral antagonism","volume":"8","author":"Nan","year":"2017","journal-title":"Front Immunol"},{"issue":"10","key":"2021031515350999300_B36","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.4049\/jimmunol.171.10.5034","article-title":"Reprogramming of IL-10 activity and signaling by IFN-\u03b3","volume":"171","author":"Herrero","year":"2003","journal-title":"J Immunol"},{"issue":"6 Pt 1","key":"2021031515350999300_B37","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1067\/mai.2000.107604","article-title":"IL-4\/IL-13 signaling beyond JAK\/STAT","volume":"105","author":"Jiang","year":"2000","journal-title":"J Allergy Clin Immunol"},{"issue":"31","key":"2021031515350999300_B38","doi-asserted-by":"crossref","first-page":"19625","DOI":"10.1074\/jbc.272.31.19625","article-title":"A Kaposi\u2019s sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit","volume":"272","author":"Molden","year":"1997","journal-title":"J Biol Chem"},{"issue":"1","key":"2021031515350999300_B39","doi-asserted-by":"crossref","first-page":"20122","DOI":"10.7448\/IAS.18.1.20122","article-title":"Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi","volume":"18","author":"Gopal","year":"2015","journal-title":"J Int AIDS Soc"},{"issue":"14","key":"2021031515350999300_B40","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1097\/QAD.0000000000001567","article-title":"HIV-associated Kaposi sarcoma and related diseases","volume":"31","author":"Gon\u00e7alves","year":"2017","journal-title":"AIDS"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/6\/1660\/1802727\/advancesadv2020004058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/6\/1660\/1802727\/advancesadv2020004058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T15:36:02Z","timestamp":1615822562000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/6\/1660\/475480\/Characteristics-and-outcomes-of-KSHV-associated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,3,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020004058","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]}}}